Atopic dermatitis (AD) is a common disease that is associated with atopic and nonatopic
comorbidities. There has been a growing interest in this area of AD, because presence or …

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

Background Studies found associations between atopic dermatitis (AD) and various
comorbidities. Objective To appraise evidence of the association between AD and …

Background Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody,
targets thymic stromal lymphopoietin, a cytokine that is implicated in the pathogenesis of …

Importance Janus kinase (JAK) inhibitors are an effective treatment option for patients with
certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but …

Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD);
clarity about drug class safety considerations in the context of AD is important. Baricitinib, an …

Background Moderate-to-severe atopic dermatitis (AD) is increasingly recognized as a
systemic disease, largely due to proteomic blood studies. There are growing efforts to …

Atopic dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is
characterized by persistent itch and marked redness. AD is associated with an increased …

Background Atopic eczema is a common and debilitating condition associated with
depression and anxiety, but the nature of this association remains unclear. Objective To …

Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated
with a high skin‐related health burden, typically starting in childhood and often persisting …